Meda acquires OTC products

Meda has acquired three well established OTC products from Norgine, a Dutch pharma company. The products are Pyralvex (relief of pain associated with e.g. aphthous ulcers), Spasmonal (treatment of for example Irritable Bowel Syndrome) and Waxsol (ear drops). The largest product is Pyralvex, which has a turnover of about 90 MSEK. Total annual sales for the products are about 190 MSEK and the majority of sales are generated in Europe. The purchase price is 540 MSEK which equals an EBITDA* multiple of about 5.

”OTC products is a growing segment. This acquisition of well known OTC brands further strengthens our presence in this area”, said Anders Lönner, CEO Meda.


Note (*): EBITDA = Earnings before interest, taxes, depreciation, and amortization.

For questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.


Documents & Links